Phaseline

Companies › Immorna Biotherapeutics

Immorna Biotherapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JCXH-105
srRNA-based vaccine for Herpes Zoster prevention
–Phase 2Herpes Zoster (HZ)Mar 2027
JCXH-108
mRNA-based vaccine against RSV
–Phase 1Respiratory Syncytial Virus (RSV)Dec 2026
JCXH-211
PD-1 checkpoint inhibitor
PDCD1Phase 1Malignant Solid TumorsMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06564194JCXH-108Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseDec 2026
NCT06581575JCXH-105Phase 2Herpes Zoster (HZ)Infectious diseaseMar 2027
NCT06781125JCXH-211Phase 1Malignant Solid TumorsOncologyMar 2028
NCT06781125JCXH-211Phase 1Malignant Solid TumorsOncologyMar 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

Shanghai Juncell Therapeutics Binhui Biopharmaceutical Inventprise LimmaTech Biologics SK Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.